These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. Pedersen TR Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729 [TBL] [Abstract][Full Text] [Related]
27. Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. Zheng PP; Li J; Kros JM Med Res Rev; 2018 Jan; 38(1):325-376. PubMed ID: 28862319 [TBL] [Abstract][Full Text] [Related]
28. Statins and cancer: current and future prospects. Osmak M Cancer Lett; 2012 Nov; 324(1):1-12. PubMed ID: 22542807 [TBL] [Abstract][Full Text] [Related]
29. The potential of statins as part of anti-cancer treatment. Sleijfer S; van der Gaast A; Planting AS; Stoter G; Verweij J Eur J Cancer; 2005 Mar; 41(4):516-22. PubMed ID: 15737555 [TBL] [Abstract][Full Text] [Related]
30. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Herrmann J Nat Rev Cardiol; 2020 Aug; 17(8):474-502. PubMed ID: 32231332 [TBL] [Abstract][Full Text] [Related]
31. The statins as anticancer agents. Chan KK; Oza AM; Siu LL Clin Cancer Res; 2003 Jan; 9(1):10-9. PubMed ID: 12538446 [TBL] [Abstract][Full Text] [Related]
32. The role of statins in cancer prevention and treatment. Stamm JA; Ornstein DL Oncology (Williston Park); 2005 May; 19(6):739-50; discussion 753-4. PubMed ID: 15971450 [TBL] [Abstract][Full Text] [Related]
33. Nanomedicine And Nanotheranostics: Special Focus on Imaging of Anticancer Drugs Induced Cardiac Toxicity. Setia A; Challa RR; Vallamkonda B; Satti P; Mehata AK; Priya V; Kumar S; Muthu MS Nanotheranostics; 2024; 8(4):473-496. PubMed ID: 38961885 [TBL] [Abstract][Full Text] [Related]
34. [Cardiotoxicity of anticancer therapies. Towards the implementation of cardio-oncology units]. Hameau R; Gabrielli L; Garrido M; Guzmán AM; Retamal I; Vacarezza MJ; Greig D; Ocqueteau M; Sánchez C; Pizarro M; Corvalán A; Lavandero S; Castro PF; Martínez G Rev Med Chil; 2018 Jan; 146(1):68-77. PubMed ID: 29806680 [TBL] [Abstract][Full Text] [Related]
35. Cardiovascular toxicity in antitumor therapy: biological and therapeutic insights. Lin X; Ma X; Zhao S; Yao J; Han L; Jing Y; Xue X Trends Cancer; 2024 Oct; 10(10):920-934. PubMed ID: 39097431 [TBL] [Abstract][Full Text] [Related]
36. In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation. L'Abbate S; Chianca M; Fabiani I; Del Franco A; Giannoni A; Vergaro G; Grigoratos C; Kusmic C; Passino C; D'Alessandra Y; Burchielli S; Emdin M; Cardinale DM J Cardiovasc Transl Res; 2022 Oct; 15(5):1143-1162. PubMed ID: 35312959 [TBL] [Abstract][Full Text] [Related]
37. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031 [TBL] [Abstract][Full Text] [Related]
39. The role of metabolic diseases in cardiotoxicity associated with cancer therapy: What we know, what we would know. L'Abbate S; Russo I; Kusmic C Life Sci; 2020 Aug; 255():117843. PubMed ID: 32464123 [TBL] [Abstract][Full Text] [Related]
40. [Molecular mechanisms of the cardiotoxic action of anthracycline antibiotics and statin-induced cytoprotective reactions of cardiomyocytes]. Tursunova NV; Klinnikova MG; Babenko OA; Lushnikova EL Biomed Khim; 2020 Sep; 66(5):357-371. PubMed ID: 33140729 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]